Condition (MeSH)
Scleritis
ClinicalTrials.gov lists 18 trials for Scleritis or a narrower condition beneath it. National Eye Institute (NEI) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
18 of the 18 trials are tagged with Scleritis itself; the rest are tagged with a narrower condition beneath it.
When did Scleritis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2013 | 2 |
| 2012 | 4 |
| 2011 | 1 |
| 2007 | 2 |
| 2006 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 18 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Scleritis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 3 |
| Phase 2 | 2 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 6 |
How many Scleritis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 10 |
| Terminated | 3 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Scleritis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Eye Institute (NEI) | 5 |
| Singapore National Eye Centre | 1 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 1 |
Which drugs are being tested for Scleritis? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RITUXIMAB | 1 |
| (CP-6890,550) Tofacitinib | 1 |
| INFLIXIMAB | 1 |
| PSI-697 | 1 |
| Gevokizumab | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone Phosphate Ophthalmic Solution | 1 |
| ACTH (Acthar) Gel | 1 |
| Immunosuppressive Agents | 1 |
| Acthar low dose (40 U) | 1 |
| No Intervention: Observational Cohort | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Scleritis trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 1 | 1 |
| cutaneous melanoma | 1 | 1 |
| squamous cell carcinoma | 1 | 1 |
Which publications cover Scleritis? (36)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. | The British journal of ophthalmology | 2018 | Yes |
| Ophthalmic manifestations in patients with inflammatory bowel disease: A review. | World journal of gastroenterology | 2017 | Yes |
| Gevokizumab in the Treatment of Autoimmune Non-necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial. | American journal of ophthalmology | 2016 | Yes |
| Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. | American journal of ophthalmology | 2015 | Yes |
| Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. | Ocular immunology and inflammation | 2014 | Yes |
Showing 5 of 36 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.